F
irst chemically synthesized by Dalmer and Walter in 1934 (4) , pyrazinamide has probably attracted as much attention as rifampin in the treatment of tuberculosis (TB). By targeting ribosomal protein S1, thereby inhibiting trans-translation of nonreplicating persisters in an acidic microenvironment rather than actively multiplying tubercle bacilli (30) , pyrazinamide has demonstrated sterilizing activity comparable to that of rifampin, when given together with streptomycin and isoniazid (9) . Synergism between rifampin and pyrazinamide has been demonstrated by a reduction in the proportion of positive 2-month cultures and relapse rates (11) . While there is clinical evidence for using fluoroquinolones (21, 41) , second-line injectable drugs (SLIDs) (1, 20) , and streptomycin (15) in the treatment of multidrug-resistant (MDR) tuberculosis (TB), corresponding evidence about the role of pyrazinamide in the treatment of MDR-TB is scarce (10, 24) . The less favorable treatment outcomes among MDR-TB cases with resistance to all first-line TB drugs than those among other MDR-TB cases that harbored bacillary strains susceptible to ethambutol, streptomycin, or pyrazinamide might allude to a potentially important role of pyrazinamide in the treatment of pyrazinamide-susceptible MDR-TB (19) . A recent study that reported the use of a gatifloxacin-based regimen among treatmentnaïve MDR-TB patients (36) and our recent report on the feasibility of giving shorter treatment for selected MDR-TB patients to achieve cure (16) might also suggest a treatment-shortening role of pyrazinamide in pyrazinamide-susceptible MDR-TB. Despite the unparalleled effectiveness of pyrazinamide as a scavenger of persisters (22, 30) , it remains uncertain whether pyrazinamide may add much to the treatment of MDR-TB in the presence of active drugs such as fluoroquinolones. Thus, it appears to be necessary to better delineate the role of pyrazinamide in MDR-TB treatment, especially when the unrivaled activity of pyrazinamide may be harnessed in the formulation of novel regimens that contain diarylquinoline (TMC207) (38) or nitroimidazo-oxazine (PA-824) (26) .
In terms of drug use and drug susceptibility, there can be only four subgroups of patients: drug users with drug-susceptible disease, drug users with drug-resistant disease, drug nonusers with drug-susceptible disease, and drug nonusers with drug-resistant disease. As the effect of a drug must be exerted through use of a drug with in vivo activity, which is indirectly evaluated by drug susceptibility testing (DST), the role of a drug can be evaluated in an observational study by examining either drug susceptibility among drug users or drug use in comparison with nonuse. Selection for pyrazinamide use or nonuse may be biased by DST results and other clinical factors. Routinely done in Lowenstein-Jensen medium, DST results for pyrazinamide and second-line drugs in Hong Kong are often available at least 1 to 2 months after starting MDR-TB treatment. Pyrazinamide is commonly given alongside second-line drugs in the treatment of MDR-TB. Pyrazinamide nonuse might suggest selection bias due to favorable clinical fac-tors. Thus, the role of pyrazinamide may be better evaluated by examining the association between treatment outcomes and pyrazinamide susceptibility among pyrazinamide users, rather than pyrazinamide use in comparison with nonuse. In fact, the same approach has been used to demonstrate the roles of fluoroquinolones (21, 41) , second-line injectable agents (1, 20) , and streptomycin (15) in the treatment of MDR-TB. Using updated data for a published MDR-TB cohort (16) that had been studied with prior approval from the Ethics Committee in the Department of Health in Hong Kong, this study aimed at evaluating the role of pyrazinamide in fluoroquinolone-based treatment of MDR-TB by estimating the adjusted risk ratio (ARR) of treatment outcome due to pyrazinamide use with susceptibility.
MATERIALS AND METHODS
By searching a territory-wide TB registry of 359 MDR-TB patients diagnosed between September 1996 and December 2009, we assembled a cohort of 194 MDR-TB patients given fluoroquinolone-containing regimens. Data collection was facilitated by a well-established health infrastructure with support from a World Health Organization (WHO)-designated supranational TB reference laboratory. Treatment outcome was evaluated by two endpoints: sputum culture conversion within 90 days after commencement of second-line treatment (early sputum culture conversion) and cure or treatment completion by 2 years after commencement of second-line treatment (treatment success). Sputum culture conversion was defined by the occurrence of two consecutive negative cultures of samples taken at least 30 days apart with no subsequent recurrence of a positive culture (39) . In accordance with WHO guidelines (39), cure was defined as completion of treatment according to the program protocol with at least five consecutive negative cultures from sputum samples collected at least 30 days apart in the last 12 months of treatment, and treatment completion was defined as completion of treatment with fewer than five consecutive negative cultures in the last 12 months of treatment. Second-line treatment referred to the use of a treatment regimen comprising one or more drugs listed in groups 2 to 5 according to classification by WHO (39), except for streptomycin. Unfavorable treatment outcome included death from any cause during treatment, default, treatment failure, relapse, or inability to allocate to a treatment outcome that has been defined by WHO guidelines (36, 39) . Only drug use exceeding 1 month was counted. Data were extracted by review of clinical records.
To optimize inclusion of major confounders and exclusion of nonconfounding variables, we followed basic principles in epidemiological studies with emphasis on the strength of association rather than statistical significance (27) . We screened potential confounders by examining risk ratios in univariate analysis rather than P values from the chi-square test (with or without Yates' correction for continuity) or Fisher's exact test. A potential confounder must meet two criteria (27) . First, it must be at least weakly associated with both the exposure factor (pyrazinamide use with susceptibility) and outcome (treatment success or early sputum culture conversion). Risk ratios of Ն1.2 or Յ0.9 were used to denote at least a weak association (25) . Second, a potential confounder must individually cause at least a 10% change in the coefficient of the exposure factor upon inclusion in robust Poisson regression, which is probably the best available method for estimating adjusted risk ratios (44) . Before multivariable analysis, multicollinearity was examined using the variance inflation factor, which was considered unacceptable when its value exceeded 1.4.
Statistical analysis was done in SPSS, version 15.0. Table 1 shows a comparison between subgroup A and each of the other three subgroups. Compared with subgroup A, each of the three other subgroups showed comparable patient and disease characteristics. Subgroup A differed significantly from subgroup B as well as subgroup D in terms of drug susceptibility pattern and drug use. Respective proportions with bacillary susceptibility to ofloxacin, SLIDs, ethionamide, pyrazinamide, and cycloserine were significantly higher in subgroup A than subgroup B. The proportion that used cycloserine was significantly lower in subgroup A than subgroup B. The proportion of patients using fewer than four drugs with activity in vitro was significantly lower in subgroup A than subgroup B. The respective proportions with early sputum culture conversion and treatment success were both significantly higher in subgroup A than subgroup B. A similar pattern was observed in the comparison between subgroups A and D. The respective proportions with bacillary susceptibility to ofloxacin, SLIDs, ethionamide, pyrazinamide, and ethambutol were significantly higher in subgroup A than subgroup D. The proportion with use of ethambutol was significantly higher in subgroup A than subgroup D, whereas the respective proportions with use of cycloserine and para-aminosalicylic acid (PAS) were significantly lower in subgroup A than subgroup D. The proportion of patients using fewer than four drugs with activity in vitro was significantly lower in subgroup A than subgroup D. The proportion with early sputum culture conversion was significantly higher in subgroup A than subgroup D, but proportions with treatment success were comparable. Subgroups A and C (the two subgroups with pyrazinamide-susceptible MDR-TB) had comparable drug susceptibility patterns, but the proportion that used cycloserine and PAS was significantly higher among pyrazinamide nonusers (subgroup C). The respective proportions with early sputum culture conversion and treatment success were comparable between subgroups A and C. Table 2 shows the results of univariate analysis of factors that may confound the association between early sputum culture conversion and pyrazinamide use with susceptibility. Table 3 summarizes the procedures and results of robust Poisson regression analysis of early sputum culture conversion. A total of 11 factors showed at least a weak association with both early sputum culture conversion and pyrazinamide use with susceptibility. Eight factors resulted in a change of at least 10% in the coefficient of pyrazinamide use with susceptibility when they were individually included in the robust Poisson regression analysis. Excluding four factors by consideration of multicollinearity left four factors that may potentially confound the association between early sputum culture conversion and pyrazinamide use with susceptibility: use of ethambutol, use of PAS, and bacillary susceptibility to ofloxacin and ethionamide. Taking into account these four factors, robust Poisson regression analysis showed that the adjusted risk ratio of early sputum culture conversion due to pyrazinamide use with susceptibility was 1.38 (95% CI, 0.89 to 2.12) in comparison with pyrazinamide use with resistance (subgroup B), 0.99 (95% CI, 0.81 to 1.22) in comparison with pyrazinamide nonuse with susceptibility (subgroup C), and 1.09 (95% CI, 0.84 to 1.42) in comparison with pyrazinamide nonuse with resistance (subgroup D) (see footnotes in Table 3) . Tables 4 and 5 Table 5 ).
RESULTS

Figure
The adjusted risk ratio of treatment success due to early sputum culture conversion was 1.71 (95% CI, 1.26 to 2.33). Subgroup analysis showed similar estimates for the adjusted risk ratio: 1.63 (95% CI, 1.14 to 2.34) for subgroups A and D, 1.66 (95% CI, 1.10 to 2.50) for subgroups A and C, and 1.78 (95% CI, 1.13 to 2.78) for subgroups A and B.
DISCUSSION
It was the primary objective of this observational study to focus on the strength of association rather than statistical significance. By following basic epidemiological principles in controlling for major confounders, this study suggests that pyrazinamide use with susceptibility among pyrazinamide users considerably increases the incidence proportion of early sputum culture conversion and that of treatment success by a best estimate of 38% for both. As this magnitude of change exceeds the 15 to 20% increase in the 2-month culture conversion rate of drug-susceptible TB that re- sults from adding pyrazinamide to isoniazid and rifampin (5-8), our study suggests that pyrazinamide has an important role in fluoroquinolone-based treatment of MDR-TB. Furthermore, we found that early sputum culture conversion significantly increased the incidence proportion of treatment success by 71% (95% CI, 26% to 133%). This finding corroborated a previous study of MDR-TB patients (41) , which showed that negative sputum cultures after 2 and 3 months of therapy with ofloxacin-or levofloxacin-containing regimens were 100% predictive of cure.
Selection bias is a major problem in observational studies. While restriction, stratification, and regression analysis may help control for major confounding factors, selection bias is often not amenable to correction at the analysis stage. The much attenuated estimates of adjusted risk ratios based on a comparison that involved pyrazinamide nonusers (subgroups C and D) might be attributable to selection bias.
Our findings corroborate the latest WHO recommendation regarding the use of pyrazinamide in the treatment of MDR-TB alongside a minimum of 4 second-line drugs that are likely to be effective (10) . The WHO recommendation is weakly based on a slightly added benefit due to pyrazinamide found in one analysis included in the literature review (10) . Only one small retrospective study of MDR-TB has suggested that including both pyrazinamide and ethambutol in the treatment regimen substantially reduced the odds of treatment failure or death (24) . The current study may underline the importance of routinely ascertaining pyrazinamide susceptibility to facilitate the treatment of MDR-TB, as we have recently proposed in a review article (42a). Baseline pyrazinamide resistance among MDR-TB patients is by no means uncommon. A systematic review shows that the prevalence of pyrazinamide resistance for culture isolates of MDR M. tuberculosis is considerably higher than that for culture isolates susceptible to isoniazid and rifampin (medians, 51% versus 5%; ranges, 31% to 89% versus 0% to 9%) (3). This may be anticipated, as pyrazinamide is probably the only drug with activity against tubercle bacilli inhibited by acidic pH (23) . The WHO recommendation regarding pyrazinamide use has made no reference to pyrazinamide susceptibility testing, probably because of the technical challenges in testing pyrazinamide susceptibility in phenotypic assays (42, 42a) . With recent advances in and the significantly reduced cost of DNA sequencing (28) , it is hoped that this problem may be solved in the near future by molecular tests based on detection of pncA mutations (29) , which is reasonably reliable for predicting pyrazinamide susceptibility in the context of MDR-TB (3). Pyrazinamide use is not without a considerable risk of hepatotoxicity (2), although a retrospective study has recently suggested that hepatotoxicity may not adversely affect the outcome of treatment for MDR-TB (14) . If reliable pyrazinamide susceptibility testing results are not available, it may be prudent to weigh pyrazinamide use against treatment efficacy, tolerance, and safety.
The therapeutic effect of pyrazinamide in the treatment of MDR-TB is biologically plausible. One Russian study has suggested in vitro synergistic effects between levofloxacin and pyrazinamide (31) . It has been demonstrated in the murine TB model that a companion drug, which can be bacteriostatic (18) or preferably bactericidal (17) , is required to elicit the therapeutic benefit of pyrazinamide. In the treatment of tuberculosis with bacillary resistance to streptomycin and isoniazid, a few studies demonstrated high cure rates from combination therapy with pyrazinamide, ethionamide, and cycloserine (32, 35, 43) . By virtue of its bactericidal effect, a fluoroquinolone may be the key component in the current MDR-TB treatment regimen that elicits the therapeutic benefit of pyrazinamide. Although it remains to be proven whether bactericidal synergism between pyrazinamide and PA-824 (34), TMC207 (13, 33) , clofazimine (33) , and possibly, thioridazine (37) in the murine TB model may translate into better treatment of MDR-TB in clinical trials, our findings suggest that the therapeutic benefit of pyrazinamide in the treatment of MDR-TB should be further evaluated in randomized controlled trials with special consideration of routine pyrazinamide susceptibility testing plus a shorter treatment duration with pyrazinamide use. The current study, based on a retrospective analysis of data collected in a TB program setting, has limitations inherent to the study design. First, our sample size was insufficient for demonstrating statistical significance. Our focus was on the estimation of the adjusted risk ratio, with meticulous consideration and careful identification of major confounders. Second, some misclassification bias in sputum culture conversion would be inevitable. Similar bias would also apply to all analyzed data, including falsepositive pyrazinamide resistance due to the intrinsic problems of phenotypic pyrazinamide susceptibility testing methods (42) and the inherent limitations of drug susceptibility testing for ethionamide, PAS, and cycloserine (40) . However, such bias was probably nondifferential, with a tendency to diminish rather than inflate the strength of association (27) . Third, our findings cannot be extrapolated to the combination of pyrazinamide and other novel drugs in the pipeline. Fourth, we have not examined the optimal duration of pyrazinamide use in the treatment of MDR-TB. Unlike the case in drug-susceptible TB, whereby the activity of pyrazinamide is largely confined to the first 2 months of treatment (12) , the optimal duration of pyrazinamide use in MDR-TB may vary according to the potency of the given regimen, bacillary load, and host immunity.
In conclusion, our study suggests that pyrazinamide use with susceptibility increases the incidence proportion of early sputum culture conversion and that of treatment success by a best estimate of 38% for both. Taking into account the impact on the 2-month culture conversion rate of drug-susceptible TB by adding pyrazinamide to isoniazid and rifampin, pyrazinamide may be important in fluoroquinolone-based MDR-TB treatment.
